Here's some potentially VERY good economic news that was lost amid the weekend news flurry.  Those…
CFIF on Twitter CFIF on YouTube
Some Potentially VERY Good Economic News

Here's some potentially VERY good economic news that was lost amid the weekend news flurry.  Those with "skin in the game," and who likely possess the best perspective, are betting heavily on an upturn, as highlighted by Friday's Wall Street Journal:

Corporate insiders are buying stock in their own companies at a pact not seen in years, a sign they are betting on a rebound after a coronavirus-induced rout.  More than 2,800 executives and directors have purchased nearly $1.19 billion in company stock since the beginning of March.  That's the third-highest level on both an individual and dollar basis since 1988, according to the Washington Service, which provides data analytics about trading activity by insiders."

Here's why that's important:

Because insiders typically know the…[more]

March 30, 2020 • 11:02 am

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Jester's CourtroomLegal tales stranger than stranger than fiction: Ridiculous and sometimes funny lawsuits plaguing our courts.
Foreign Freeloading to Blame for High Drug Prices Print
By Betsy McCaughey
Wednesday, February 14 2018
The U.S. is the biggest free market for pharmaceuticals - the only place left where pharma companies can recoup their innovation costs.

Americans are suffering pharmaceutical sticker shock. But the remedy Democrats are backingprice controls on prescription drugswould inflict more harm by halting new discoveries and dooming patients waiting for cures.

Since 1950, our increasing longevityan amazing 10 extra years of life for the average Americanhas been mainly the result of pharmaceutical breakthroughs. If someone in your family has an incurable illnesscystic fibrosis, multiple sclerosis, Alzheimer'sthe idea of slowing the pace of new cures is unthinkable.

On Friday, President Donald Trump's Council of Economic Advisors proposed a safer way to make drugs affordable here: negotiate trade deals that compel foreign countries to pay fairer drug prices.

Americans consume about 46 percent of the world's brand-name drugs but supply 70 percent of patented drugmakers' profits. France, Norway, the United Kingdom, Japan, Canada, Italy and other government-run health systems buy identical drugs at bargain pricesusually half what Americans pay. These state-run health systems often threaten to exclude a drug from their country entirely, even if it could save lives, to extract a deep discount. Norway barred Roche's breast cancer drug Perjeta until the company slashed the price far below what Medicare pays.

These foreign governments know that when push comes to shove, a manufacturer will sell for a price that barely covers the cost of production, rather than not sell at all. That leaves American consumers stuck paying exorbitant prices to cover the sunk costs of researching and developing a new drug.

R & D costs are staggering: nearly $3 billion and 10 years of clinical trials, and then government approvals for each drug, with failures along the way. Drug companies like Pfizer in the U.S., Novartis in Switzerland and AstraZeneca in France have hefty profit margins25 percent on averagethe same as Silicon Valley companies and other high-risk industries.

But not just shareholders benefit. Patients have a better chance of surviving their illnesses and living longer in countries that rapidly adopt new drugs and treatments. Almost all gains in longevity since WWII are due to these innovations, reports Stanford economist Victor Fuchs. Some newer drugs also curb overall health costs, according to Columbia University economist Frank Lichtenberg. Anesthesia reversing drugs, for example, shorten hospital stays or keep people out of the hospital altogether.

Yet it is drug prices Americans experience directly. Patients are eight times likelier to fill a prescription than be hospitalized. And their high-deductible plans are clobbering them with out-of-pocket costs at the pharmacy.

No wonder drug prices are a politician's easy target. The left demands that Medicare and other U.S. government programs "negotiate" with drug companies. Who can haggle with the federal government? "Negotiate" is a euphemism for price controls that will shortchange drugmakers, dulling their incentive to innovate.

The U.S. is the biggest free market for pharmaceuticalsthe only place left where pharma companies can recoup their innovation costs.

Price control advocates would rather settle for the current state of medical knowledge than pay for drug discovery. "We cannot all have it all," says economist Austin Frakt, pointing to new, expensive drugs for hepatitis C. "The rate of innovation will eventually exceed our ability to pay for it."

Tell that to parents of infants with spinal muscular atrophy, afflicting 10,000 Americans. Or 25 million Americans suffering from other rare, incurable illnesses. For them, President Trump has a far better approach.

In his State of the Union Address, Trump decried the "very, very unfair" gap between American and foreign drug prices. He has also promised to overturn "decades of unfair trade deals." Memo to the president's trade negotiators: Start requiring foreign countries to pay fair drug prices. George W. Bush's administration made headway in a bilateral trade agreement with Australia. Ending the foreign freeloading will keep the engine of medical innovation running and save lives.

That's the choice: Accept slower cures or spread the cost fairly.


Betsy McCaughey is a senior fellow at the London Center for Policy Research and a former lieutenant governor of New York State.
COPYRIGHT 2018 CREATORS.COM

Question of the Week   
Which one of the following pandemics caused the largest number of deaths in the 20th Century alone?
More Questions
Quote of the Day   
 
"The Justice Department's chief watchdog issued an extraordinary warning Tuesday that the FBI is failing to follow its own rules when pursuing surveillance warrants in sensitive intelligence and terrorism cases, confirming that problems first exposed in the Russia collusion probe extend to other cases.DOJ Inspector General Michael Horowitz wrote FBI Director Chris Wray in a management alert memo that…[more]
 
 
—John Solomon, Just the News Editor in Chief
— John Solomon, Just the News Editor in Chief
 
Liberty Poll   

Who is most to blame for the delay in passage of the critical coronavirus economic recovery (or stimulus) bill?